There are numerous treatment options, but no one single treatment is completely effective.
Smidt et al noted a greater improvement in pain symptoms from lateral epicondylitis at 52 weeks when employing watchful waiting relative to the administration of corticosteroid injections. [11] In addition, watchful waiting was about equally as effective as physiotherapy at 52 weeks. However, corticosteroid injections were significantly better than both watchful waiting and physiotherapy at 6 weeks. [11] Tennis Elbow Sleeve
In 2006, Bisset et al investigated treating lateral epicondylitis with physiotherapy, corticosteroid injection, or watchful waiting in 198 individuals with symptoms for greater than 6 weeks. [1] Outcomes were global improvement in symptoms, pain-free grip force, and assessment of severity of complaints. There were significant reductions in all outcomes measured for corticosteroid injections over watchful waiting at 6 weeks. In the corticosteroid group, 78% reported success, versus 27% for those in the watchful waiting group. Corticosteroid injections also outperformed physiotherapy at 6 weeks, with 65% of the physiotherapy group having success versus 78% of the corticosteroid group. Physiotherapy was superior to watchful waiting at 6 weeks. However, the improvement in symptoms with corticosteroid injections was not sustained at 52 weeks.
At 52 weeks, the injection group was significantly worse on all outcomes compared with the physiotherapy group and worse on 2 of 3 measures compared with watchful waiting. Finally, at 52 weeks, there was not much of a difference in comparing physiotherapy to watchful waiting. Fifty-nine of 63 much improved or completely recovered in the physiotherapy group, versus 56 of 62 in the watchful waiting group. This study again elucidates that corticosteroid injections may have some benefit in the short term, but the long-term benefits are definitely lacking in the treatment of lateral epicondylitis. Physiotherapy demonstrated improvement versus watchful waiting at 5 weeks, with only slight improvement at 52 weeks. [1]
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac may offer some short-term relief. [12, 13] In a study with oral diclofenac, this agent improved short-term pain and function, but there was no difference noted when comparing naproxen and placebo for pain reduction in lateral epicondylitis. Corticosteroid injection demonstrated greater benefit at 4 weeks when compared with NSAIDS, but no long-term differences were seen.
A Cochrane review looked at 17 comparisons of 759 participants and noted: “There remains limited evidence from which to draw firm conclusions about the benefits or harms of topical or oral NSAIDs in treating lateral elbow pain. Although data from five placebo-controlled trials suggest that topical NSAIDs may be beneficial in improving pain (for up to 4 weeks), non-normal distribution of data and other methodological issues precluded firm conclusions.” [14]
One study demonstrated that a corticosteroid injection had superior efficacy in pain relief at 6 weeks when compared with physiotherapy that consisted of ultrasound, massage, and exercise. However, the authors noted that corticosteroid injection was not as effective as physiotherapy at 12 weeks. [11] Smidt et al found that administering a corticosteroid injection decreased pain in lateral epicondylitis at 6 weeks but not beyond that period.
A study looked at 297 patients with lateral epicondylitis and found that individuals treated with structured physical therapy had less pain than patients treated with corticosteroid injections or NSAIDs and experienced better function than those treated with corticosteroid injections. The intervention group had a lower recurrence and fewer sick leave days at the time of the visit to the healthcare center. [15]
In another study, when corticosteroid injection was compared with arm bracing, the use of a corticosteroid injection demonstrated decreased pain at 2 weeks, but there was no difference noted at 6 weeks. [16] There was also no significant difference noted in the type of steroid that was injected.
A study by Gosens et al compared corticosteroid with platelet-rich plasma (PRP) injections in patients who had refractory lateral epicondylitis symptoms for longer than 6 months. Primary outcome measures were pain and daily use of the elbow. One hundred patients blindly received either PRP or corticosteroid injection, followed by a similar standard rehabilitation protocol. Success was defined as a 25% reduction in pain on a visual analogue scale (VAS) score or on a disabilities of the arm, shoulder, and hand (DASH) score.
At 4 weeks, the corticosteroid injection group reported a 32.8% improvement in VAS scores and a 25.8% improvement in DASH scores. At 4 weeks, the PRP group had a 21% improvement in VAS scores and a 15.7% improvement in DASH scores. Both had similar improvements at 8 weeks. The PRP group had a greater and more sustained symptom improvement; the individuals were followed for longer period of time. At 12 weeks, the PRP group demonstrated a 44.8% improvement in VAS and a 43% improvement in DASH scores. At 12 weeks, the corticosteroid group reported improvements of 32.8% in VAS and 29.8% in DASH scores. These trends continued at 6 months, 12 months, 1 year, and 2 years. The PRP group continued to show improvement in VAS and DASH scores at 6 months, 12 months, and 2 years. The corticosteroid group had less successful symptom resolution the longer the individuals were followed. [17]
A study by Lebiedziński et al found that betamethasone injections give more rapid improvement, but the therapeutic effect is longer lasting in the autologous conditioned plasma group. [7]
In summary, administering a corticosteroid injection is effective in reducing pain from lateral epicondylitis in the short term, but this procedure may not be as effective in the long term.
Counterforce braces are used in an attempt to reduce the tension forces on the wrist extensor tendons, and these orthotics may be superior to lateral epicondyle bandages in reducing resting pain. [18] The brace should be applied firmly approximately 10 cm distal to the elbow joint. Use of a counterforce brace may decrease pain and increase grip strength at 3 weeks in individuals with lateral epicondylitis. [19] However, some authors believe that no firm conclusions can be drawn from the use of orthotics in the treatment of lateral epicondylitis. [20] Counterforce braces are possibly inferior in the treatment of lateral epicondylitis when compared with topical NSAIDs and corticosteroid injections.
Jafarian et al compared 3 common types of orthoses for their effect on grip strength in patients with lateral epicondylosis. [21] In a randomized controlled laboratory study in 52 patients, maximum and pain-free grip strength were assessed with the patient wearing an elbow strap orthosis, an elbow sleeve orthosis, a wrist splint, or a placebo orthosis. Use of the elbow strap and sleeve orthoses resulted in an immediate and equivalent increase in pain-free grip strength (P< 0.02); consequently, the researchers suggest that either of these types of orthosis may be used. [21] The wrist splint provided no immediate improvement in either pain-free or maximum grip strength.
A study by Altan and Kanat compared treating 50 individuals with symptoms of lateral epicondylitis for less than 12 months with either a typical counterforce forearm brace versus treatment with a 10-15° dorsiflexion wrist splint. [2] Parameters of pain at rest and with extension, sensitivity, hand grip strength, and a subjective response to treatment were measured at baseline, 2 weeks, and 6 weeks. No formal physical therapy or home exercise program was recommended. The counterforce brace group demonstrated significant reduction in pain at rest and during movement at 2 weeks, while sensitivity and grip strength were not changed at 2 weeks.
At 6 weeks, significant improvement was noted in all parameters with the implementation of counterforce bracing. The wrist splint group demonstrated improvement in all parameters measured at 2 and 6 weeks except for sensitivity at 2 weeks. Comparison of the 2 groups showed significant improvement in resting pain at 2 weeks for the wrist splint group over the counterforce brace group. No other significant differences were noted between the 2 groups. This study was limited by lack of a control group. In summary, all patients improved with either counterforce elbow bracing or wrist splint bracing at 2 and 6 weeks. Wrist splint bracing, however, demonstrated an advantage on some measured subjective and objective parameters. [2]
A study looked at the immediate effect on grip strength in treating lateral epicondylitis with 3 different kinds of orthoses, a counterforce elbow strap, a counterforce elbow sleeve, and a wrist splint versus a placebo control brace proximal to the elbow. This involved 52 subjects with symptoms of a mean duration of 18 weeks. The counterforce strap and sleeve provided an improvement in pain free grip strength; however, there were no differences between the 2 counterforce braces. The wrist splint did not change pain free grip strength compared with placebo. [3]
Garg et al randomized 42 patients with acute symptoms of lateral epicondylitis to either a wrist extension splint or a counterforce brace. Again, there was no control, nonbraced, group. Ice and home stretching exercised were recommended to both groups. Clinical outcomes were measured at the time of enrollment and at 6 weeks of follow up. Both groups overall improved at the 6-week mark. Specifically looking at some of the outcomes measured, however, pain was significantly more reduced in the wrist splint group than the counterforce brace group.
At 6 weeks, significant improvement was noted in all parameters with the implementation of counterforce bracing. The wrist splint group demonstrated improvement in all parameters measured at 2 and 6 weeks, except for sensitivity at 2 weeks. Comparison of the 2 groups showed significant improvement in resting pain at 2 weeks for the wrist splint group over the counterforce brace group. No other significant differences were noted between the 2 groups. This study was limited by lack of a control, nonbraced, group. In summary, all patients improved with either counterforce elbow bracing or wrist splint bracing at 2 and 6 weeks. Wrist splint bracing, however, demonstrated an advantage on some measured subjective and objective parameters. [22]
Najafi et al investigated the benefits of a spiral hand-forearm splint that restricted wrist extension and limited supination and pronation of the forearm in patients with lateral epicondylitis for at least 3 weeks. The normal range of supination and pronation were 98° and 85°, but the new splint reduced these rates by 59% and 53%, respectively, compared with the without-splint condition in healthy subjects. After 4 weeks of continually wearing the splint, pain was about a quarter of what it was at baseline, grip strength had improved by 18%, and function had also greatly increased based on the DASH score. This study was limited by its being non-blinded, with no control group. [23]
Saremi et al performed a non-randomized double-blinded clinical trial examining the immediate effects of a newly designed orthosis (wedged brace) for patients with lateral epicondylitis. This small study included 12 individuals who had symptoms for at least 6 weeks. The main difference between this brace and the traditional counterforce strap is that there are “two separated medium- density fiberboard wedges incorporated into the proximal part.” Patients wore the new brace for 48 hours and then were evaluated. The new strap was removed for at least 48 hours before patients were given the traditional tennis elbow strap. Patients were evaluated a second time after 48 hours of wearing the traditional strap. [24]
Grip strength and pain (VAS) were the outcome measures. Pain scores were lower than baseline when using both braces, but the new orthosis, on average, gave a 2-point lower VAS score than the traditional brace. While wearing the braces, patients’ grip strength increased some from baseline, but there was not a statistical significance between the two straps.
Until recently, there was little evidence demonstrating a benefit in using extracorporeal shock wave therapy (ECSWT) to treat patients with lateral epicondylitis. [25]
A study by Aydin et al reported that both ECSWT and wrist-extensor splints resulted in improvements in pain and handgrip strength in 67 patients with lateral epicondylitis. [26]
Twenty-six patients participated in a non-blinded, controlled study that evaluated both clinical and functional improvement in muscle strength in patients with lateral epicondylitis who had symptoms for at least 6 months that were treated using ECSWT. Improvement was measured using VAS, Mayo Elbow Performance Index scores, and handgrip strength. A decrease in pain and a recovery of function were noted. However, a decrease in muscular handgrip strength was also noted after treatment. The patients were followed up for only 1 month after the intervention. [27]
A small prospective, non-controlled, non-blinded study was performed in Istanbul using ECSWT as a treatment for lateral epicondylitis in 12 patients. Mean duration of symptoms was 3.5 ± 3.2 months. Each person received 1 session of treatment a week for 3 weeks. Measurements of VAS score and grip strength were taken at baseline and 1 month following treatment. The average VAS scores decreased by about 1.5 points and the average grip strength scores increased by about 16 points, which was considered significant. Researchers concluded that ECSWT is an effective treatment in the short term (1 month). More research must be done to determine the long-term efficacy of ECSWT in the treatment of lateral elbow pain. [28]
Koksal et al compared ECSWT in patients with acute lateral epicondylitis versus those with chronic lateral epicondylitis. The study included a total of 55 patients. There was no control group. Twenty-four patients had been experiencing symptoms for less than 3 months and were considered acute; 30 patients had symptoms for longer than 3 months and were considered chronic. Each patient in both groups received the same 3 sessions of ECSWT that were 5 minutes long and were spread out by 3 days between sessions. Progress was checked at 2, 12, and 24 weeks following the conclusion of the third session. Pain was measured while resting, stretching, while lifting a chair, while working, when pressed, and at nighttime. VAS scores in both groups had improved in all categories at the 2-week checkup. Scores continued to improve for the subsequent follow-up visits as well. This result led researchers to conclude that ECSWT is an effective treatment for both acute and chronic lateral epicondylitis. [29]
Lizis conducted a randomized study of 50 participants to compare ECSWT to ultrasound therapy for the treatment of lateral epicondylitis symptoms from about 15 months in patients who had failed 6 months of previous treatments. The ECSWT group received treatment once a week for 5 weeks. The ultrasound group had 3 treatments per week for a total of 10 sessions. Follow-up was done immediately after treatment and again after 3 months. Prior to treatment, VAS scores were similar among the groups. Both groups reported decreased pain at both follow-up visits, but the improvement was statistically greater in the ECSWT group than in the ultrasound group. [30]
Trentini et al completed a small non-controlled observational study (n=37) that examined ultrasound-guided ECSWT as a treatment for chronic lateral epicondylitis. Seventeen of the patients had previously received physical therapy, but the others had not. Patients received 3-4 weekly sessions, with a small portion continuing for 8-10 weeks owing to relapsing symptoms. Physical therapy was not prescribed after treatment. VAS and QuickDASH (qDASH) scores significantly decreased from baseline to the final follow-up (24.8-month average; range, 14-45). The number of patients who had tenderness at palpation, pain with resisted wrist extension, or pain with resisted third finger extension decreased significantly as well. However, among individuals who did not respond to the first cycle of ECSWT, only 33% responded to further treatments. [31]
Beyazal et al compared non–ultrasound-guided corticosteroid injection with ECSWT for the treatment of chronic lateral epicondylitis in 64 patients. There was no placebo group. In the corticosteroid group, 20 mg of methylprednisolone acetate with 1 mL of prilocaine was used. VAS scores improved at both follow-up visits for both groups at 4 and 12 weeks. The percentage of improvement was higher in the ECSWT group at both follow-up visits when compared with the corticosteroid injection group. At the conclusion of the study, VAS scores in the ECSWT group had improved by 90%, compared with a 30% improvement in the corticosteroid injection group. [32]
Lin et al published a study looking at a novel method of treating chronic refractory lateral epicondylitis with ultrasound-guided percutaneous radiofrequency thermal lesioning (RTL). [10] They enrolled 34 patients (35 elbows) with symptoms of lateral epicondylitis for greater than 6 months in whom previous interventions had failed. Patients were examined at baseline and then at 1, 3, and 6 months after the index procedure. Outcomes measures were VAS at rest and activity, QuickDASH scores, and the Modified Mayo Clinic Performance Index (MMCPI) for the elbow.
Significant pain reductions were noted at 1, 3, and 6 months of follow-up. Grip strength improved significantly at 3 and 6 months of follow-up but not significantly at the 1 month of follow-up. DASH and MMCPI scores improved significantly at all follow-up measurements. Eighty-five percent of the patients reported pain relief at the 1-month follow-up. Ninety-one percent of the subjects reported good-to-excellent satisfaction results at 6 months. Five patients needed a repeat procedure because of unsatisfactory symptom relief, and, of these, 4 reported satisfactory results after the second procedure. No change was noted on ultrasound in the thickness of the origin of the extensor tendon. [10]
Systemic reviews and meta-analyses have demonstrated some evidence of short-term improvement in pain reduction at 2 to 8 weeks in patients suffering from lateral epicondylar pain. [20, 33] However, other studies demonstrated insufficient evidence to recommend its use. [13]
The Beijing Sport Institute performed a non-blinded prospective study comparing the treatment of external humeral epicondylitis with electroacupuncture, massage, and blocking therapy versus treatment using only blocking therapy. Eighty-three patients were divided equally into two groups. The electrotherapy, massage, and blocking group received electrotherapy once a day for 10 days. Massage was administered once a week for 10 weeks. Blocking therapy was administered twice, with 1 week in between treatments. Patients in both groups saw improvements on VAS, grip strength index, and Mayo elbow performance scores after 6 months. At 12 months, the control group relapsed. By 24 months, both groups had relapsed. These treatment options may be effective in delaying recurrence but are not a cure for the condition. [34]
Wong et al conducted a randomized study comparing the treatment effects of ECSWT and acupuncture in patients with lateral epicondylitis. The ECSWT group received 1 session per week for 3 weeks. The acupuncture group received 2 sessions per week for 3 weeks. Outcomes were assessed at baseline, immediately after treatment, and then again 2 weeks later. Both groups had significant improvement in pain, but there was no significant difference between the groups at either follow-up. This follow-up is very short, and long-term conclusions cannot be made. [35]
Autologous blood injections are thought to initiate an inflammatory process and promote improved healing of degenerative tissue via the relatively atraumatic injection itself as well as by providing necessary cellular and humoral mediators to induce a healing cascade. [36] Edwards and Calandruccio studied 28 people in whom conservative therapy had failed to resolve the symptoms of lateral epicondylitis. [37] The participants were given a cock-up wrist splint and told to avoid any other bracing or physical therapy for 3 weeks. A home exercise program was initiated at week 3. The study demonstrated that 22 (79%) of the 28 patients had a reduction in Nirschl pain scores over 9.5 months after autologous blood injection therapy. [37] Most often, this occurred after only one injection. However, this study is limited, as it lacked a control group. [11]
A study by Connell et al looked at ultrasound-guided autologous blood injections as a treatment for 35 individuals with lateral epicondylitis confirmed on MRI. These patients had symptoms for a median of almost 14 months, and conservative therapy had not been successful. Outcomes were measured as reduction in VAS and Nirschl pain scores at 4 weeks and 6 months. No formal physical therapy or home exercise program was recommended. Autologous blood injections demonstrated significant improvements in VAS and Nirschl pain measurements at 4 weeks and at 6 months. Autologous blood injections also demonstrated statistical improvements in tendon thickness, interstitial cleft formation, echoic foci, hyperechoic change, and neovascularity. [12]
A small study compared autologous blood, corticosteroid, and saline injection in the treatment of lateral epicondylitis of less than 6 months’ duration in 28 individuals. Patients were followed for 6 months after the injections, and the outcomes measured were reduction in DASH scores and pain- and disease-specific functional scores. Participants were not given any formal physical therapy regimen or orthotics. They were simply given a standard sheet of stretching exercises to which compliance was not measured. All 3 injections caused a decrease in DASH scores at 2 weeks and 2 months and a significant decrease at 6 months; however, there were no significant differences between the 3 groups. In addition, patient reported scores of pain and function also improved among all 3 groups. [13]
Kazemi et al performed a single blinded, randomized clinical trial comparing autologous blood injections to corticosteroid injection in 60 individuals with lateral elbow tendinopathy during the past year. [16] Bracing, physical therapy, or anti-inflammatory medications were not allowed during the duration of the study.
Outcomes were measurement of VAS pain scale, DASH questionnaire, modified Nirschl pain scores, maximum grip strength, and pain pressure threshold. Short-term follow-up was ascertained at 4- and 8-week intervals. Corticosteroid injections demonstrated improvements at 4 weeks in all outcome scores except pain pressure threshold. There was no significant improvement from 4-8 weeks in the steroid group for any of the outcomes except a decrease in limb pain and a worsening of grip strength. The autologous blood group demonstrated statistically significant improvements in all outcomes measured at 4 and 8 weeks. Autologous blood injections demonstrated superiority to corticosteroid injections at 4 and 8 weeks in all parameters measured. [16]
Ozturan et al performed a 3-armed randomized trial of 60 patients with symptoms consistent with lateral epicondylitis for greater than 6 months with no previous physical therapy in the past 3 months to a corticosteroid injection, autologous blood injection, or ECSWT. [38] Outcomes measured were Thomsen provocative test scores, upper extremity functional scores, and maximal grip strength. Assessment was at 4, 12, 26, and 52 weeks. Sixteen of the 20 patients in the autologous blood group received a second injection at 6 weeks.
In this study, at 4 weeks, the corticosteroid group had a significant improvement in a functional score and Thomsen provocative tests over both the autologous blood group and the ECSWT group. There was no difference between the autologous blood group and the ECSWT at 4 weeks. There was no significant difference in these tests at the 12-week mark. Following patterns from other studies, the corticosteroid group performed less well the longer that the patients were followed up. There was a statistically significant improvement for the autologous blood and ECSWT groups compared with the corticosteroid groups at the 26- and 52-week follow-up appointments for functional scores and Thomsen provocative tests.
Grip strength was also assessed at the same time intervals and noted an improvement for the corticosteroid group at 4 weeks compared with autologous blood and ECSWT. There was no difference noted in grip strength at 12 weeks between the three groups. ESWT performed better at the 26-week follow-up with respect to grip strength when compared with autologous blood and corticosteroid injections. At 52 weeks, there was no significant difference between the three groups with respect to grip strength. At 52 weeks, the success rate for corticosteroid injections was 50%, compared with 83% for autologous blood injections and 89% for ECSWT treatments.
This study supported the idea the corticosteroid injections can be helpful for temporary and short-term improvement in patients with chronic lateral epicondylitis, but that autologous blood and ECSWT tend to have more lasting improvements. [39]
A very small study also demonstrated the effectiveness of autologous blood injections for the treatment of chronic lateral epicondylitis. However, the patients were placed in a long arm cast for 3 weeks after the injection. Long arm cast immobilization is not the standard of care after proinflammatory injections. [40]
A non-blinded, non-controlled study by Bostan et al investigated the long-term effects of autologous blood injections for recalcitrant lateral epicondylitis in 20 patients (21 elbows). All patients had failed conservative therapies and had symptoms for at least 3 months. Autologous blood (3 mL) was drawn from the contralateral arm and injected to the area of maximum tenderness. These were blinded injections with a “dry needling” technique. Four patients received a second injection at the end of the 4th week because of persistent symptoms. Patients were examined at 2, 4, and 6 weeks; at 6 months; and at 1 and 3 years. [41]
The average VAS score decreased significantly from baseline, and the decrease continued through the 3-year follow up. Significant improvement in grip strength and the Nirschl score was also noted and persisted throughout the 3-year follow up. [41]
Arik et al compared non-US guided autologous whole blood and corticosteroid injection as treatment methods for individuals with lateral epicondylitis symptoms for an average of about 4 months. Eighty patients were randomly divided into 2 equal groups. The researchers found that patients who received corticosteroids improved faster for the first 15 days but then started to decline at day 90. The patients who received whole blood improved steadily, and their scores eventually surpassed those of the corticosteroid group when pain, function, and grip strength were analyzed at 90 and 180 days after the intervention. [42]
A systematic review and meta-analysis by Chen et al reported that platelet-rich plasma (PRP) may reduce pain associated with lateral epicondylitis and rotator cuff injuries. [43] Another study demonstrated significantly reduced pain when treating chronic elbow tendinosis with buffered PRP. Mishra and Pavelko evaluated 140 patients with elbow epicondylar pain; 20 patients continued to consider surgical intervention after conservative therapy failed to resolve their symptoms. [44] These patients were then administered either a single percutaneous injection of PRP or bupivacaine (control group).
At 8 weeks after therapy, the authors demonstrated a 60% pain improvement in the group who received PRP compared with a 16% pain improvement in the control group. [44] At 6 months and final follow-up (mean, 25.6 mo; range, 12-38 mo), the patients who had received PRP continued to report significant pain reduction.
A study compared PRP therapy injections with autologous blood injections in 28 patients who had symptoms of lateral epicondylitis for greater than 3 months. Patients were instructed on home physical therapy consisting of eccentric exercises. Reevaluation was done at 6 weeks, 3 months, and 6 months to assess symptoms on a VAS pain scale and a Liverpool elbow score, which measured range of motion, activity level, and ulnar nerve function. On the VAS scale, both groups demonstrated improvements at all follow-up appointments. The PRP group had better results at each visit, with statistically better results at 6 weeks. Both groups also showed improvements on the Liverpool elbow score at all visits, with no significant differences noted. [17]
Creany et al compared PRP injections to autologous blood injections in 130 individuals with refractory symptoms of lateral epicondylitis in whom conservative physical therapy had failed. These injections were performed under ultrasound guidance, and each group had two injections, at initial visit and then 1 month later. The outcome measured was the Patient-Related Tennis Elbow Evaluation (PRTEE) score. Success was defined as a 25-point improvement in this score. Measurements were obtained at 0, 1, 3, and 6 months. At 6 months, there was a 66% success rate in the PRP group and a 72% success rate in the autologous blood group. However, 20% of the autologous blood group went on to have surgery, versus 10% of the PRP group. [45]
More recently, Raeissadat et al performed a randomized clinical trial involving 40 patients who had symptoms consistent with lateral epicondylitis for greater than 3 months. They looked at improvement in pain and function when comparing PRP with autologous blood. Both groups were given a counterforce brace and a home exercise program. At 4 weeks, Mayo and VAS scores significantly improved in both the PRP and the autologous blood groups. However, only the PRP group demonstrated significant improvement at 8 weeks with respect to the VAS and Mayo scores. [46]
A non-blinded, non-controlled study looked at 40 patients with lateral epicondylitis symptoms of greater than 3 months. It compared treating lateral epicondylitis with a non-ultrasound guided single injection of 2 mL of PRP vs a single injection of 2 mL of whole autologous blood. Patients were asked to refrain from heavy labor, wear a tennis elbow strap, and perform a 5-week physical therapy program following injection. Pain (VAS score) and functional improvement (modified Mayo clinic performance index) were measured before the injection as a baseline and then again at 4 and 8 weeks after the operation. At 4 weeks both the VAS and Mayo scores had improved significantly for both groups. At 8 weeks, however, the PRP group scores had continued to improve, whereas the whole blood group scores had remained about the same. This study was limited by very short follow-up. [47]
A non-blinded, non-controlled study compared the long-term effects of non-ultrasound guided injections of PRP versus autologous whole blood in patients with chronic tennis elbow. Seventy-six patients who had experienced at least 3 months of chronical lateral humeral epicondylitis (LHE) symptoms were randomly divided into 2 groups. The first group received a single injection of 2 mL of autologous leukocyte-rich PRP. The second group received 2 mL of autologous whole blood. After the injection, both groups were prescribed the use of a tennis elbow strap and stretching and strengthening exercises. Pain and function were assessed using the VAS, Mayo score, and Physical Performance Test (PPT). Measurements were taken at 0, 4, and 8 weeks and then again at 6 and 12 months. [48]
Both groups saw significant improvement in all 3 scores at each follow-up interval. There was not, however, a significant difference between the groups. The investigators concluded that both methods are effective treatment to treat chronic LHE, with the benefit of the effects persisting long term. PRP was not superior to autologous whole blood long term. [48]
Krogh et al examined whether a single injection of PRP is more effective than placebo (saline) or glucocorticoid in reducing pain in adults with lateral epicondylitis after 3 months. The authors concluded that neither injection of PRP nor glucocorticoid was superior to saline with regard to pain reduction in lateral epicondylitis at the primary end point at 3 months. However, injection of glucocorticoid had a short-term pain-reducing effect at 1 month in contrast to the other therapies. Injection of glucocorticoid in lateral epicondylitis reduces both color Doppler activity and tendon thickness compared with PRP and saline. [49]
A non-blinded, randomized prospective study of 60 lateral epicondylitis patients by Yadav et al compared PRP therapy (single injection of 1 m L with a 1 million platelet count) to methyl-prednisolone local injection. The duration of symptoms ranged from 1 to 6 months (mean, 2.26-1.93). After a 2-week wash-out of treatments (NSAIDs and analgesics), both groups received a single non-ultrasound guided injection in the same location of their designated treatment. There was no physical therapy after the intervention. [50]
VAS scores and grip strength were better in the steroid group at 15 days and at 1 month, but the PRP group was significantly superior at the 3-month follow-up. Functional outcome (qDASH) gradually increased at each follow-up in both groups, with the steroid group having more improvement until the 3-month follow-up, when the PRP patients reported significantly better outcomes. [50]
Behera et al examined how leukocyte-poor PRP compared with bupivacaine injection as a treatment for lateral epicondylitis. The study was small, including only 25 patients, but the groups were randomized. The groups had failed conservative therapies for more than 3 months. All patients received a single ultrasound-guided injection and were instructed to rest for 2 days and then begin an at-home physical therapy program that included stretching and strengthening. At baseline the results between the two groups were roughly the same. At the 1-month follow-up, the PRP group had a lower percentage of improvement than the bupivacaine group, but at 3 months, 6 months, and 1 year, the PRP results were superior. The researchers found PRP to be an acceptable treatment for improving function and pain based on the VAS, modified MAYO, and Nirschl scores. [52]
Mishra et al evaluated the clinical value of tendon needling with PRP in patients with chronic tennis elbow compared with an active control group. No significant differences were found at 12 weeks in this study; however, at 24 weeks, clinically meaningful improvements were found in patients treated with leukocyte-enriched PRP compared with an active control group. [53]
Arirachakaran et al performed a systematic review and network meta-analysis of 10 studies. This analysis compared PRP to autologous whole blood and to steroid injection in patients with lateral epicondylitis. PRP injection significantly improved pain and Patient Rated Tennis Elbow Evaluation (PRTEE) score when compared with autologous blood injection and steroid injection after 2 months. Autologous whole blood injection was the best treatment for improving disabilities scores (DASH, PRTEE) and increasing pressure threshold (PPT) both within and after 2 months. The chances of adverse effects from PRP injection and steroid injection were not significantly different, but autologous blood injection had a significantly higher likelihood of adverse effects when compared with steroid injection. [54]
Chou et al conducted a meta-analysis of randomized controlled trials involving autologous blood injection for treatment of lateral epicondylitis. A total of nine studies were included: three compared autologous blood injection with PRP, and six compared autologous blood injection with corticosteroid injection. There was a high degree of heterogeneity among the studies. Autologous blood injection were better at decreasing pain than corticosteroid injection. PRP performed better than autologous blood injection in treating lateral epicondylitis, but the authors state that it was not significant when they accounted for bias. [55]
Montalvan et al performed a double-blinded, randomized, controlled study assessing the efficacy of 2 PRP injections as a treatment for lateral epicondylitis in 50 persons who reported symptoms for no more than 3 months. They had not received any previous treatments. Each group received a single 2 mL ultrasound-guided injection of either PRP or saline. Four weeks later each patient received a second injection in the same manner. Rehabilitation and physical therapy, as well as local corticosteroid injection, were not allowed. Follow-ups were done at 1, 3, 6, and 12 months, and both efficacy and safety were evaluated at each. VAS scores decreased in both groups at a similar rate and were only 0.1 different (1-10 scale) at the 12-month follow-up. The difference between groups' averages was not statistically significant at any follow-up. At the 12-month follow-up, both groups reported 14 patients as asymptomatic, meaning they had a VAS score of less than 1. [56]
Tonk et al conducted a non-blinded, non-controlled study comparing PRP treatment with low-level laser therapy in patients who had poorly defined subacute to chronic lateral elbow pain. Patients were initially treated with a brace, nonsteroidal analgesics, and cold therapy for 7 days before beginning the study. Eighty-one patients who did not respond to these methods were admitted into the study. Thirty-nine patients received non-ultrasound guided PRP injections, and 42 received low-level laser therapy. Both methods reduced pain based on the Nirschl pain score. Laser therapy showed better short-term results until about 2 months post baseline. At this time, PRP patients began to see significantly lower pain scores than laser therapy when followed for 12 months, suggesting that PRP is a better treatment for long-term pain reduction. [57]
Tetschke et al compared autologous conditioned plasma with low-level laser applications in 52 patients who had at least 3 months of lateral epicondylitis symptoms. All patients had previous unsuccessful physiotherapy or medical treatment. The autologous conditioned plasma group received 3 non-ultrasound guided fan-like injections in a single session. The low-level laser group received 12 total applications. All groups followed up with standard physical therapy. Follow-ups were done at 2, 6, and 12 months. In both groups, improvements in VAS and DASH scores were seen at each follow-up, with the autologous conditioned plasma group's scores trending to be better on average. [58]
A retrospective cohort study by Karaduman et al investigated ultrasound-guided PRP injections (36 patients, 60 elbows) versus an open surgical release procedure, the Nirschl technique (44 patients, 55 elbows). Patients had symptoms for at least 12 months and were unresponsive to at least 6 months of conservative treatment. All patients’ rehabilitation was done by the same physical therapist according to the same rehabilitation protocol. Patients were evaluated at 1, 2, and 6 months and at 1 year. In regard to the Mayo Elbow score and VAS, the PRP group had consistent improvement to the 1-year follow-up and was significantly better than the surgical group at all follow-ups. Grip strength steadily improved in both groups but was statistically better in the PRP group at all follow-up visits. [59]
A meta-analysis by Hohmann et al indicated that in patients with lateral epicondylitis, better results are achieved at 1 month from corticosteroid injections than from PRP injections; however, the opposite is true at 3 and 6 months. The researchers used pooled estimates from VAS and DASH scores. They recommended caution in interpreting the results because of the studies’ bias risk and low to moderate quality. [60]
Similarly, a study by Kivrak et al found that corticosteroid injections are effective in the short term but that PRP and autologous blood injections are more effective in the long term. At the 6-month examination, the VAS, DASH, and Nirschl scores of patients who had received PRP or autologous blood injections had improved significantly more than those of patients treated with corticosteroids. [61]
A novel approach to the treatment of chronic lateral epicondylitis is hyaluronate injections. Petrella et al looked at treating 331 individuals with lateral elbow pain of greater than 3 months with either 1% sodium hyaluronate or saline. This was a double-blinded study, and each group received an injection at baseline and then 1 week later. Participants had not had any recent injections. They were instructed on postinjection care of rest, ice, compression, elevation (RICE), and no formal physical therapy was prescribed. Primary outcomes were improvement on VAS at rest and after elbow grip testing. VAS pain at rest and after grip testing was significantly better in the hyaluronate group versus the saline group. There was also improvement in secondary outcomes of grip strength, patient global satisfaction, and assessment of normal elbow function in the hyaluronate group versus the saline group. These differences persisted at the 90-day and 365-day follow-up appointments. [62]
Kumai et al conducted a non-blinded, non-controlled study examining high-molecular-weight hyaluronic acid as a treatment for 61 patients with a variety of different enthesopathies. Of those patients, 16 experienced symptoms consistent with lateral epicondylitis, with a mean duration of symptoms ranging from 1.5 to 55 months. Each patient received up to 2.5 mL of hyaluronate via a non-ultrasound guided injection. There was no specified rehabilitation protocol after the intervention. Of the patients with lateral epicondylitis, 62.5% noted a decrease in VAS score by at least 2 cm at follow-up 1 week after the intervention. This study is limited by low numbers, lack of control and blinding, and very short-term follow-up. [63]
Polidocanol is a vascular sclerosant. Zeisig et al looked at 32 patients with symptoms of chronic lateral epicondylitis in whom conservative therapy had failed. [64] Some patients had previously had injections (cortisone = 24, botulism = 5). Eccentric strengthening was previously used in 22 participants, and 2 participants had tendon-lengthening surgery. Symptoms were present for more than 3 months, and there had been no previous treatment in the past 3 months. Groups were randomized to either an ultrasound-guided blinded injection of polidocanol or lidocaine plus epinephrine. Patients were followed for 3 months for primary endpoints of satisfaction with treatment and elbow pain during grip activities of daily life. At 3 months, if they still had pain, they were offered another injection of polidocanol. They were then followed for a total of 12 months. At 3 and 12 months, there was a significant improvement in patient satisfaction and in VAS grip pain from baseline for both groups. However, there was no significant difference between the groups.
Branson et al conducted an assessor-blinded, randomized, controlled trial comparing the effects of ultrasound-guided injections of corticosteroid, autologous blood, and polidocanol in treating 44 patients with chronic lateral epicondylitis symptoms of at least 2 months' duration. All patients had evidence of neovascularization on Doppler ultrasound studies. The corticosteroid group received a single injection, and the autologous blood group and the sclerosant group each received 2 injections separated by 4 weeks. All patients saw a physical therapist and were instructed on an eccentric home exercise program. Participants were assessed at baseline, 4, 12, and 26 weeks. [65]
The corticosteroid group had superior results when compared with the autologous blood and polidocanol groups at 4 weeks. Polidocanol was significantly superior to corticosteroid injection at 26 weeks. Patients who received autologous blood injections also performed better, and these differences neared significance. There were no significant differences between corticosteroid injections and autologous blood injections at any time point. Patients in the corticosteroid group had a higher rate of recurrent symptoms than those in both the autologous blood and sclerosant groups. Polidocanol and autologous blood had no significant difference at any of the follow-up evaluations. [65]
Wong et al demonstrated that an injection of botulinum toxin decreased patients' pain from lateral epicondylitis at 4-12 weeks when compared with saline injection; however, there was an increased incidence of side effects in the botulinum toxin–treated group, which included digit paresis and weakness of finger extension. [66] In addition, the trial was small (60 patients), most of the patients were women, and the blinding of the study may have been affected by some of the patients possibly knowing which treatment they received (4 patients experienced digit paresis and may have correctly deduced they received the botulinum toxin injection).
A study by Placzek et al also demonstrated improvement in painful symptoms arising from lateral epicondylitis when botulinum toxin injections were used compared with saline. [67] However, another randomized controlled trial demonstrated no significant difference when comparing injections of botulinum toxin and saline in the treatment of lateral epicondylitis. [68]
A double-blind randomized controlled study did not find significant differences between corticosteroid and botulinum toxin injections. [69] Another study by Creuzé et al reported that botulinum toxin A 40 IU injected into the extensor carpi radialis brevis muscle was an effective treatment for chronic lateral epicondylar tendinopathy that was otherwise resistant to medical treatment. [70]
A double-blinded, randomized, active drug-controlled trial by Lin et al compared the treatment effects of two different sites of botulinum toxin injection with a non-ultrasound guided steroid injection in 16 patients with lateral epicondylitis (19 elbows). Almost all of the patients had symptoms for less than 3 months. Group A received a 1 mL injection containing 20 U of botulinum toxin 1 cm distal to the painful lateral epicondyle. Group B received a 1 mL injection also containing 20 U of botulinum at the most tender point of the common extensor muscle. Group C received a 1 mL injection containing 40 mg of triamcinolone acetonide 1 cm distal to the painful lateral epicondyle. The primary outcome measure was VAS.
All 3 treatments were successful at reducing pain for at least 16 weeks. At 4 weeks of follow-up, VAS scores for groups A, B, and C were 20.4, 10.1, and 46.0, respectively, which was statistically significant. The botulinum toxin groups exhibited a trend toward diminished pain ratings as time progressed, whereas the steroid group reported less reduction as time progressed, but the differences were not statistically significant. A small decrease in grip strength was observed in the botulinum toxin groups at 4 weeks, and this decrease was less evident at 8 and 12 weeks. [71]
Topical nitrates are thought to stimulate collagen synthesis and improve healing. Paoloni et al demonstrated that application of topical nitrates is an effective method of treating pain from lateral epicondylitis. [72]
A study evaluated the effect of topical glyceryl trinitrate (GTN) on lateral epicondylitis. Forty patients with chronic symptoms (of 4-8 months' duration), who were selected based on pain, tenderness, and positive pain-stimulating maneuvers, were divided into 2 equal groups. One received a GTN patch that was applied once daily to the area where maximal tenderness was felt. The second group applied a placebo patch in the same manner. Results were evaluated using VAS and calculated with the Mann-Whitney U-test and chi squared test.
The GTN group had lower VAS scores (3.15 vs 6.45) and less elbow pain after 3 weeks of treatment than the control group. No patient in the control group had good results; in contrast, 90% of those in the treatment group (18 people) reported success. At the 6-month follow-up, the VAS score gap between the groups had increased further. The treatment group had an average score of 0.7, whereas that of the control group was 4.85. The researchers determined that these data were statistically significant, making topical GTN an effective treatment for chronic lateral epicondylitis. [73]
In a non-blinded, non-controlled prospective study, Singh et al presented evidence that bone marrow injection could be a potential treatment option for lateral epicondylitis. A total of 26 male and female patients, who were experiencing symptoms of lateral epicondylitis but had not been previously treated, completed the study. There was no mention of chronicity of symptoms. The injections were given without ultrasound guidance. Significant improvements were observed, as measured by the PRTEE scale at short- to moderate-term follow-up at 2, 6, and 12 months. [74]
A case series examined the effects of autologous tenocyte injections for 17 patients who had chronic symptoms of lateral epicondylitis for more than 6 months despite conservative treatments. Ultrasonography or MRI was used to confirm the lesion. No adverse event was reported at either biopsy or injection sites. Three weeks after patella tendon biopsy, patients received a single injection of autologous tenocytes. No supervised physical therapy was recommended. Clinical evaluation revealed an improvement in mean VAS scores; QuickDASH and grip strength scores also significantly improved over the 12-month follow-up period. Wang et al also noted improvement in the grade of tendinopathy on a validated MRI scoring system at 12 months. [75]
Wang et al conducted a follow-up study that examined the long-term effects (4.5-year average follow-up) on their patients who underwent ultrasound-guided autologous tenocyte injections to treat severe refractory lateral epicondylitis. Significant improvements in pain, function, and structural repair were seen at the 1-year follow-up, and this study aimed to determine whether the improvements were maintained up to 5 years later. For the small group that completed the trial (n=15), VAS scores had improved by 78%, QuickDASH by 84%, and grip strength by 208% at the long-term follow-up assessment. [76]
Lee et al conducted a very small (n=12) pilot study investigating the potential therapeutic effects of allogenic adipose-derived mesenchymal stem cells (allo-ASC) for patients with lateral epicondylitis. The study had two groups of 6 people each. Group 1 received a 1 mL ultrasound-guided injection of 106 cells. Group 2 also received a 1 mL ultrasound-guided injection but with 107 cells. There was no control or placebo group.
Follow-up evaluations were performed at 6, 12, 26, and 52 weeks. VAS scores progressively decreased across the follow-up assessments. Group 2 scores improved at a greater rate until 26 weeks, when there was no statistical difference between the groups. Group 2 VAS scores did slightly increase from 26 to 52 weeks but remained significantly below the baseline. Group 1 scores gradually decreased and did not increase between any two follow-up evaluations.
Performance (Mayo Elbow Performance Index [MEPI]) increased to 6 weeks but then appeared to have plateaued to 26 weeks. At 52 weeks, the MEPI was slightly lower than at 26 weeks for both groups but still significantly improved from baseline. There was no statistically significant difference between the 2 groups in regard to the MEPI at any follow-up evaluation.
Structural improvement was also measured. The defect area at the long and short axis decreased from baseline at 6, 12, and 26 weeks. At 52 weeks, however, the area of the defect was larger (both long and short axis) than it was at 26 weeks but still smaller than baseline. This could be a sign of relapse; however, the data are not conclusive on this matter. [77]
The Mayo department of orthopedics performed a small non-controlled study testing the efficacy of percutaneous ultrasonic tenotomy (Tenex) for chronic elbow tendinosis. Twelve patients had lateral epicondylitis, specifically, and had been experiencing symptoms for at least 3 months. After treatment, patients had activity restrictions and follow-up appointments. Results were determined by measurements on the VAS and QuickDASH scale. Both scores improved from baseline to 6 weeks, and continued improvement was seen at each subsequent follow-up visit at 3, 6, and 12 months. There were no procedural complications. [78]
Chesterton et al investigated whether transcutaneous electrical nerve stimulation (TENS) provides favorable outcomes when used in conjunction with primary care management. They performed a randomized controlled trial with 241 adults. The control group received primary care management alone. Elbow pain intensity was reported by patients using a scale of 1-10 at 0 and 6 weeks, as well as at 6 and 12 months. The researchers found no significant pain difference between the groups at any of the benchmarks and concluded that TENS is not an effective treatment method. [79]
There is not much evidence for low-level laser therapy as an effective treatment for patients with pain from lateral epicondylitis. [80]
Dundar et al randomized 93 patients with lateral elbow pain of less than 3 months' duration to receive high-intensity laser therapy (HILT), sham HILT, or a counterforce brace. The HILT treatment groups were treated once a day for 15 days during a period of 3 weeks. The HILT and brace groups showed significant improvement in multiple areas of measurement including pain, strength, and function, whereas the sham HILT treatment group did not. This improvement was noted at both 4 and 12 weeks. However, the improvement was not reflected on ultrasonographic evaluation before and after treatment. [81]
Salli et al compared HILT and the use of an epicondylitis bandage (counterforce brace) as treatments for chronic lateral epicondylitis. Patients in the HILT group (n=31) were treated 10 times total, 5 times a week for 2 weeks. The first 4 sessions were 75 seconds long. The next 6 doses were administered in 30-second intervals for 12 total minutes. Patients in the bandage group (n= 4) were instructed to wear the bandage for 6 weeks.
Following treatment, VAS scores decreased both at rest and during activity in the two groups. There was not a statistical significance in the improvement of VAS scores during activity between the two groups, but there was for resting VAS scores in favor of HILT. DASH scores also decreased in both groups, but the decrease was larger in the HILT group. There was no control group, and the follow-up was only 6 weeks. [82]
Akkurt et al performed an observational study evaluating the effectiveness of HILT for chronic lateral epicondylitis symptoms. The 23 patients (37 elbows) were treated with HILT for 5 sessions per week for 2 weeks (10 sessions in total), and then they were followed up for 6 months. Significant improvements were noted in VAS activity scores, DASH scores, hand grip strength, and quality of life assessments when comparing baseline scores with the scores at 6 months' assessment. [83]
Strength training, exercise, and stretching have been shown to decrease pain in patients with lateral epicondylitis. [20] It is important to have the patients progress from concentric to eccentric exercises and then stress eccentric exercises when the individual is able to tolerate them. NSAID iontophoresis is also an effective method of treating pain from lateral epicondylitis, but corticosteroid iontophoresis has not been shown to be effective. [20] Occupational therapy can be employed in an attempt to modify the workplace environment to eliminate aggravating activities.
Ultrasound (US) therapy has demonstrated modest pain reduction, [20, 80] although US- and color Doppler-guided intratendinous injections with polidocanol in the extensor origin have shown promising clinical results, [64] and there is insufficient evidence to support the use of transverse friction, soft-tissue therapy in the treatment of lateral epicondylitis. [84]
Sevier et al conducted a randomized, parallel, single-blinded (physician) two-group study that examined the relatively new noninvasive treatment Astym and its potential value in treating lateral epicondylitis. In group 1, the Astym group, 36 of the 46 patients met the resolution criteria, compared with 18 of the 44 patients in group 2, the eccentric exercise group. The Astym group had greater reductions in pain (DASH) and increased grip strength over the eccentric exercise group. Improvements were maintained at the 6- and 12-month follow-up visits. Additionally, the patients who did not respond to exercise were allowed to receive Astym treatment after the 4-week randomized control period was over. These patients also had statistically significant improvement. [85]
Surgical intervention can be very effective for refractory cases of lateral epicondylitis, with a large percentage of individuals reporting improvement in their symptoms. However, surgical intervention is only indicated after 6 months of conservative care has failed to relieve the patient's symptoms. A long-term follow-up study (mean, 130 mo; range, 106-173 mo) of arthroscopic treatment of recalcitrant lateral epicondylitis by Baker and Baker demonstrated that arthroscopic removal of pathologic tendinosis tissue can be a successful treatment strategy in such cases. [86]
It is important that each case is evaluated individually, because some patients may have multiple relapses or lack progression through therapy. These patients may opt for surgery after a shorter trial of conservative care.
Gradual return to play is recommended, with an emphasis on the patient employing improved form to avoid aggravating activities and techniques. The athlete should be able to perform pain-free ROM activities. Continued attention should be placed on a strengthening and conditioning program.
Attention to proper form and technique will decrease the risk of developing tendinosis of the lateral elbow extensor muscles. Other preventive strategies include the following:
Bisset L, Beller E, Jull G, Brooks P, Darnell R, Vicenzino B. Mobilisation with movement and exercise, corticosteroid injection, or wait and see for tennis elbow: randomised trial. BMJ. 2006 Nov 4. 333(7575):939. [QxMD MEDLINE Link]. [Full Text].
Altan L, Kanat E. Conservative treatment of lateral epicondylitis: comparison of two different orthotic devices. Clin Rheumatol. 2008 Aug. 27(8):1015-9. [QxMD MEDLINE Link].
Jafarian FS, Demneh ES, Tyson SF. The immediate effect of orthotic management on grip strength of patients with lateral epicondylosis. J Orthop Sports Phys Ther. 2009 Jun. 39(6):484-9. [QxMD MEDLINE Link].
Roetert EP, Brody H, Dillman CJ, Groppel JL, Schultheis JM. The biomechanics of tennis elbow. An integrated approach. Clin Sports Med. 1995 Jan. 14(1):47-57. [QxMD MEDLINE Link].
Rossi J, Vigouroux L, Barla C, Berton E. Potential effects of racket grip size on lateral epicondilalgy risks. Scand J Med Sci Sports. 2014 Dec. 24 (6):e462-470. [QxMD MEDLINE Link].
Li FX, Fewtrell D, Jenkins M. String vibration dampers do not reduce racket frame vibration transfer to the forearm. J Sports Sci. 2004 Nov-Dec. 22(11-12):1041-52. [QxMD MEDLINE Link].
Lebiedziński R, Synder M, Buchcic P, Polguj M, Grzegorzewski A, Sibiński M. A randomized study of autologous conditioned plasma and steroid injections in the treatment of lateral epicondylitis. Int Orthop. 2015 Nov. 39 (11):2199-203. [QxMD MEDLINE Link].
Herquelot E, Guéguen A, Roquelaure Y, Bodin J, Sérazin C, Ha C, et al. Work-related risk factors for incidence of lateral epicondylitis in a large working population. Scand J Work Environ Health. 2013 Nov. 39(6):578-88. [QxMD MEDLINE Link].
Karabinov V, Georgiev GP. Lateral epicondylitis: New trends and challenges in treatment. World J Orthop. 2022 Apr 18. 13 (4):354-64. [QxMD MEDLINE Link]. [Full Text].
Lin CL, Lee JS, Su WR, Kuo LC, Tai TW, Jou IM. Clinical and ultrasonographic results of ultrasonographically guided percutaneous radiofrequency lesioning in the treatment of recalcitrant lateral epicondylitis. Am J Sports Med. 2011 Nov. 39 (11):2429-35. [QxMD MEDLINE Link].
Edwards SG, Calandruccio JH. Autologous blood injections for refractory lateral epicondylitis. J Hand Surg Am. 2003 Mar. 28(2):272-8. [QxMD MEDLINE Link].
Connell DA, Ali KE, Ahmad M, Lambert S, Corbett S, Curtis M. Ultrasound-guided autologous blood injection for tennis elbow. Skeletal Radiol. 2006 Jun. 35(6):371-7. [QxMD MEDLINE Link].
Wolf JM, Ozer K, Scott F, Gordon MJ, Williams AE. Comparison of autologous blood, corticosteroid, and saline injection in the treatment of lateral epicondylitis: a prospective, randomized, controlled multicenter study. J Hand Surg Am. 2011 Aug. 36(8):1269-72. [QxMD MEDLINE Link].
Pattanittum P, Turner T, Green S, Buchbinder R. Non-steroidal anti-inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults. Cochrane Database Syst Rev. 2013. 5:CD003686. [QxMD MEDLINE Link].
Nilsson P, Baigi A, Swärd L, Möller M, Månsson J. Lateral epicondylalgia: a structured programme better than corticosteroids and NSAID. Scand J Occup Ther. 2012 Sep. 19(5):404-10. [QxMD MEDLINE Link].
Kazemi M, Azma K, Tavana B, Rezaiee Moghaddam F, Panahi A. Autologous blood versus corticosteroid local injection in the short-term treatment of lateral elbow tendinopathy: a randomized clinical trial of efficacy. Am J Phys Med Rehabil. 2010 Aug. 89(8):660-7. [QxMD MEDLINE Link].
Thanasas C, Papadimitriou G, Charalambidis C, Paraskevopoulos I, Papanikolaou A. Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: a randomized controlled clinical trial. Am J Sports Med. 2011 Oct. 39 (10):2130-4. [QxMD MEDLINE Link].
Altan L, Kanat E. Conservative treatment of lateral epicondylitis: comparison of two different orthotic devices. Clin Rheumatol. 2008 Aug. 27 (8):1015-9. [QxMD MEDLINE Link].
Borkholder CD, Hill VA, Fess EE. The efficacy of splinting for lateral epicondylitis: a systematic review. J Hand Ther. 2004 Apr-Jun. 17(2):181-99. [QxMD MEDLINE Link].
Bisset L, Paungmali A, Vicenzino B, Beller E. A systematic review and meta-analysis of clinical trials on physical interventions for lateral epicondylalgia. Br J Sports Med. 2005 Jul. 39(7):411-22; discussion 411-22. [QxMD MEDLINE Link].
Jafarian FS, Demneh ES, Tyson SF. The immediate effect of orthotic management on grip strength of patients with lateral epicondylosis. J Orthop Sports Phys Ther. 2009 Jun. 39(6):484-9. [QxMD MEDLINE Link].
Garg R, Adamson GJ, Dawson PA, Shankwiler JA, Pink MM. A prospective randomized study comparing a forearm strap brace versus a wrist splint for the treatment of lateral epicondylitis. J Shoulder Elbow Surg. 2010 Jun. 19(4):508-12. [QxMD MEDLINE Link].
Najafi M, Arazpour M, Aminian G, Curran S, Madani SP, Hutchins SW. Effect of a new hand-forearm splint on grip strength, pain, and function in patients with tennis elbow. Prosthet Orthot Int. 2016 Jun. 40 (3):363-8. [QxMD MEDLINE Link].
Saremi H, Chamani V, Vahab-Kashani R. A Newly Designed Tennis Elbow Orthosis With a Traditional Tennis Elbow Strap in Patients With Lateral Epicondylitis. Trauma Mon. 2016 Jul. 21 (3):e35993. [QxMD MEDLINE Link].
Buchbinder R, Green SE, Youd JM, et al. Shock wave therapy for lateral elbow pain. Cochrane Database Syst Rev. 2005 Oct 19. CD003524. [QxMD MEDLINE Link].
Aydın A, Atiç R. Comparison of extracorporeal shock-wave therapy and wrist-extensor splint application in the treatment of lateral epicondylitis: a prospective randomized controlled study. J Pain Res. 2018. 11:1459-1467. [QxMD MEDLINE Link].
Notarnicola A, Quagliarella L, Sasanelli N, Maccagnano G, Fracella MR, Forcignanò MI, et al. Effects of extracorporeal shock wave therapy on functional and strength recovery of handgrip in patients affected by epicondylitis. Ultrasound Med Biol. 2014 Dec. 40 (12):2830-40. [QxMD MEDLINE Link].
Bayram K, Yesil H, Dogan E. Efficacy of extracorporeal shock wave therapy in the treatment of lateral epicondylitis. North Clin Istanb. 2014. 1 (1):33-38. [QxMD MEDLINE Link].
Köksal i, Güler O, Mahiroğulları M, Mutlu S, Çakmak S, Akşahin E. Comparison of Extracorporeal Shock Wave Therapy in Acute and Chronic Lateral Epicondylitis. ACTA ORTHOP TRUMATOL Turc. 2015. 49 (5): 465-70. [QXMD MedLine Link].
Lizis P. Analgesic effect of extracorporeal shock wave therapy versus ultrasound therapy in chronic tennis elbow. J Phys Ther Sci. 2015 Aug. 27 (8):2563-7. [QxMD MEDLINE Link].
Trentini R, Mangano T, Repetto I, Cerruti P, Kuqi E, Trompetto C, et al. Short- to mid-term follow-up effectiveness of US-guided focal extracorporeal shock wave therapy in the treatment of elbow lateral epicondylitis. Musculoskelet Surg. 2015 Sep. 99 Suppl 1:S91-7. [QxMD MEDLINE Link].
Beyazal MS, Devrimsel G. Comparison of the effectiveness of local corticosteroid injection and extracorporeal shock wave therapy in patients with lateral epicondylitis. J Phys Ther Sci. 2015 Dec. 27 (12):3755-8. [QxMD MEDLINE Link].
Ramsay DJ, Bowman MA, Greenman, PE, et al, for the NIH Consensus Panel. NIH Consensus Conference. Acupuncture. JAMA. 1998 Nov 4. 280(17):1518-24. [QxMD MEDLINE Link].
Li X, Zhou K, Zhang E, Qi Z, Sun W, Xu L, et al. Therapeutic effect of electroacupuncture, massage, and blocking therapy on external humeral epicondylitis. J Tradit Chin Med. 2014 Jun. 34 (3):261-6. [QxMD MEDLINE Link].
Wong CW, Ng EY, Fung PW, Mok KM, Yung PS, Chan KM. Comparison of treatment effects on lateral epicondylitis between acupuncture and extracorporeal shockwave therapy. Asia Pac J Sports Med Arthrosc Rehabil Technol. 2017 Jan. 7:21-26. [QxMD MEDLINE Link].
Calandruccio JH, Steiner MM. Autologous Blood and Platelet-Rich Plasma Injections for Treatment of Lateral Epicondylitis. Orthop Clin North Am. 2017 Jul. 48 (3):351-357. [QxMD MEDLINE Link].
Edwards SG, Calandruccio JH. Autologous blood injections for refractory lateral epicondylitis. J Hand Surg [Am]. 2003 Mar. 28(2):272-8. [QxMD MEDLINE Link].
Ozturan KE, Yucel I, Cakici H, Guven M, Sungur I. Autologous blood and corticosteroid injection and extracoporeal shock wave therapy in the treatment of lateral epicondylitis. Orthopedics. 2010 Feb. 33(2):84-91. [QxMD MEDLINE Link].
Kazemi M, Azma K, Tavana B, Rezaiee Moghaddam F, Panahi A. Autologous blood versus corticosteroid local injection in the short-term treatment of lateral elbow tendinopathy: a randomized clinical trial of efficacy. Am J Phys Med Rehabil. 2010 Aug. 89(8):660-7. [QxMD MEDLINE Link].
Karimi Mobarakeh M, Nemati A, Fazli A, Fallahi A, Safari S. Autologous blood injection for treatment of tennis elbow. Trauma Mon. 2013 Winter. 17(4):393-5. [QxMD MEDLINE Link]. [Full Text].
Bostan B, Balta O, Aşçı M, Aytekin K, Eser E. Autologous Blood Injection Works for Recalcitrant Lateral Epicondylitis. Balkan Med J. 2016 Mar. 33 (2):216-20. [QxMD MEDLINE Link].
Arik HO, Kose O, Guler F, Deniz G, Egerci OF, Ucar M. Injection of autologous blood versus corticosteroid for lateral epicondylitis: a randomised controlled study. J Orthop Surg (Hong Kong). 2014 Dec. 22 (3):333-7. [QxMD MEDLINE Link].
Chen X, Jones IA, Park C, Vangsness CT Jr. The Efficacy of Platelet-Rich Plasma on Tendon and Ligament Healing: A Systematic Review and Meta-analysis With Bias Assessment. Am J Sports Med. 2018 Jul. 46 (8):2020-2032. [QxMD MEDLINE Link].
Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006 Nov. 34(11):1774-8. [QxMD MEDLINE Link].
Creaney L, Wallace A, Curtis M, Connell D. Growth factor-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: a prospective, single-blind, randomised trial of autologous blood injections versus platelet-rich plasma injections. Br J Sports Med. 2011 Sep. 45(12):966-71. [QxMD MEDLINE Link].
Raeissadat SA, Sedighipour L, Rayegani SM, Bahrami MH, Bayat M, Rahimi R. Effect of Platelet-Rich Plasma (PRP) versus Autologous Whole Blood on Pain and Function Improvement in Tennis Elbow: A Randomized Clinical Trial. Pain Res Treat. 2014. 2014:191525. [QxMD MEDLINE Link]. [Full Text].
Raeissadat SA, Sedighipour L, Rayegani SM, Bahrami MH, Bayat M, Rahimi R. Effect of Platelet-Rich Plasma (PRP) versus Autologous Whole Blood on Pain and Function Improvement in Tennis Elbow: A Randomized Clinical Trial. Pain Res Treat. 2014. 2014:191525. [QxMD MEDLINE Link].
Raeissadat SA, Rayegani SM, Hassanabadi H, Rahimi R, Sedighipour L, Rostami K. Is Platelet-rich plasma superior to whole blood in the management of chronic tennis elbow: one year randomized clinical trial. BMC Sports Sci Med Rehabil. 2014. 6:12. [QxMD MEDLINE Link].
Krogh TP, Fredberg U, Stengaard-Pedersen K, Christensen R, Jensen P, Ellingsen T. Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. Am J Sports Med. 2013 Mar. 41(3):625-35. [QxMD MEDLINE Link].
Yadav R, Kothari SY, Borah D. Comparison of Local Injection of Platelet Rich Plasma and Corticosteroids in the Treatment of Lateral Epicondylitis of Humerus. J Clin Diagn Res. 2015 Jul. 9 (7):RC05-7. [QxMD MEDLINE Link].
Gautam VK, Verma S, Batra S, Bhatnagar N, Arora S. Platelet-rich plasma versus corticosteroid injection for recalcitrant lateral epicondylitis: clinical and ultrasonographic evaluation. J Orthop Surg (Hong Kong). 2015 Apr. 23 (1):1-5. [QxMD MEDLINE Link].
Behera P, Dhillon M, Aggarwal S, Marwaha N, Prakash M. Leukocyte-poor platelet-rich plasma versus bupivacaine for recalcitrant lateral epicondylar tendinopathy. J Orthop Surg (Hong Kong). 2015 Apr. 23 (1):6-10. [QxMD MEDLINE Link].
Mishra AK, Skrepnik NV, Edwards SG, Jones GL, Sampson S, Vermillion DA, et al. Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients. Am J Sports Med. 2014 Feb. 42(2):463-71. [QxMD MEDLINE Link].
Arirachakaran A, Sukthuayat A, Sisayanarane T, Laoratanavoraphong S, Kanchanatawan W, Kongtharvonskul J. Platelet-rich plasma versus autologous blood versus steroid injection in lateral epicondylitis: systematic review and network meta-analysis. J Orthop Traumatol. 2016 Jun. 17 (2):101-12. [QxMD MEDLINE Link].
Chou LC, Liou TH, Kuan YC, Huang YH, Chen HC. Autologous blood injection for treatment of lateral epicondylosis: A meta-analysis of randomized controlled trials. Phys Ther Sport. 2016 Mar. 18:68-73. [QxMD MEDLINE Link].
Montalvan B, Le Goux P, Klouche S, Borgel D, Hardy P, Breban M. Inefficacy of ultrasound-guided local injections of autologous conditioned plasma for recent epicondylitis: results of a double-blind placebo-controlled randomized clinical trial with one-year follow-up. Rheumatology (Oxford). 2016 Feb. 55 (2):279-85. [QxMD MEDLINE Link].
Tonk G, Kumar A, Gupta A. Platelet rich plasma versus laser therapy in lateral epicondylitis of elbow. Indian J Orthop. 2014 Jul. 48 (4):390-3. [QxMD MEDLINE Link].
Tetschke E, Rudolf M, Lohmann CH, Stärke C. Autologous proliferative therapies in recalcitrant lateral epicondylitis. Am J Phys Med Rehabil. 2015 Sep. 94 (9):696-706. [QxMD MEDLINE Link].
Karaduman M, Okkaoglu MC, Sesen H, Taskesen A, Ozdemir M, Altay M. Platelet-rich plasma versus open surgical release in chronic tennis elbow: A retrospective comparative study. J Orthop. 2016 Mar. 13 (1):10-4. [QxMD MEDLINE Link].
Hohmann E, Tetsworth K, Glatt V. Corticosteroid injections for the treatment of lateral epicondylitis are superior to platelet-rich plasma at 1 month but platelet-rich plasma is more effective at 6 months: an updated systematic review and meta-analysis of level 1 and 2 studies. J Shoulder Elbow Surg. 2023 Sep. 32 (9):1770-83. [QxMD MEDLINE Link].
Kıvrak A, Ulusoy I. Comparison of the Clinical Results of Platelet-Rich Plasma, Steroid and Autologous Blood Injections in the Treatment of Chronic Lateral Epicondylitis. Healthcare (Basel). 2023 Mar 6. 11 (5):[QxMD MEDLINE Link]. [Full Text].
Petrella RJ, Cogliano A, Decaria J, Mohamed N, Lee R. Management of Tennis Elbow with sodium hyaluronate periarticular injections. Sports Med Arthrosc Rehabil Ther Technol. 2010 Feb 2. 2:4. [QxMD MEDLINE Link]. [Full Text].
Kumai T, Muneta T, Tsuchiya A, Shiraishi M, Ishizaki Y, Sugimoto K, et al. The short-term effect after a single injection of high-molecular-weight hyaluronic acid in patients with enthesopathies (lateral epicondylitis, patellar tendinopathy, insertional Achilles tendinopathy, and plantar fasciitis): a preliminary study. J Orthop Sci. 2014 Jul. 19 (4):603-11. [QxMD MEDLINE Link].
Zeisig E, Fahlström M, Ohberg L, Alfredson H. Pain relief after intratendinous injections in patients with tennis elbow: results of a randomised study. Br J Sports Med. 2008 Apr. 42(4):267-71. [QxMD MEDLINE Link].
Branson R, Naidu K, du Toit C, Rotstein AH, Kiss R, McMillan D, et al. Comparison of corticosteroid, autologous blood or sclerosant injections for chronic tennis elbow. J Sci Med Sport. 2017 Jun. 20 (6):528-533. [QxMD MEDLINE Link].
Wong SM, Hui AC, Tong PY, et al. Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2005 Dec 6. 143(11):793-7. [QxMD MEDLINE Link]. [Full Text].
Placzek R, Drescher W, Deuretzbacher G, Hempfing A, Meiss AL. Treatment of chronic radial epicondylitis with botulinum toxin A. A double-blind, placebo-controlled, randomized multicenter study. J Bone Joint Surg Am. 2007 Feb. 89(2):255-60. [QxMD MEDLINE Link].
Hayton MJ, Santini AJ, Hughes PJ, et al. Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. J Bone Joint Surg Am. 2005 Mar. 87(3):503-7. [QxMD MEDLINE Link].
Guo YH, Kuan TS, Chen KL, Lien WC, Hsieh PC, Hsieh IC, et al. Comparison Between Steroid and 2 Different Sites of Botulinum Toxin Injection in the Treatment of Lateral Epicondylalgia: A Randomized, Double-Blind, Active Drug-Controlled Pilot Study. Arch Phys Med Rehabil. 2017 Jan. 98 (1):36-42. [QxMD MEDLINE Link].
Creuzé A, Petit H, de Sèze M. Short-Term Effect of Low-Dose, Electromyography-Guided Botulinum Toxin A Injection in the Treatment of Chronic Lateral Epicondylar Tendinopathy: A Randomized, Double-Blinded Study. J Bone Joint Surg Am. 2018 May 16. 100 (10):818-826. [QxMD MEDLINE Link].
Lin YC, Tu YK, Chen SS, Lin IL, Chen SC, Guo HR. Comparison between botulinum toxin and corticosteroid injection in the treatment of acute and subacute tennis elbow: a prospective, randomized, double-blind, active drug-controlled pilot study. Am J Phys Med Rehabil. 2010 Aug. 89 (8):653-9. [QxMD MEDLINE Link].
Paoloni JA, Appleyard RC, Nelson J, Murrell GA. Topical nitric oxide application in the treatment of chronic extensor tendinosis at the elbow: a randomized, double-blinded, placebo-controlled clinical trial. Am J Sports Med. 2003 Nov-Dec. 31(6):915-20. [QxMD MEDLINE Link].
Ozden R, Uruç V, Doăramari Y, Kalakci A, Yangle E. Management of tennis elbow in the top of the elbow. Ahta Orthoppil Turc. 2014. 48 (2): 175–80. [RDD MEDINE Link].
Singh A, Gangwar DS, Singh S. Bone marrow injection: A novel treatment for tennis elbow. J Nat Sci Biol Med. 2014 Jul. 5 (2):389-91. [QxMD MEDLINE Link].
Wang A, Breidahl W, Mackie KE, Lin Z, Qin A, Chen J, et al. Autologous tenocyte injection for the treatment of severe, chronic resistant lateral epicondylitis: a pilot study. Am J Sports Med. 2013 Dec. 41 (12):2925-32. [QxMD MEDLINE Link].
Wang A, Mackie K, Breidahl W, Wang T, Zheng MH. Evidence for the Durability of Autologous Tenocyte Injection for Treatment of Chronic Resistant Lateral Epicondylitis: Mean 4.5-Year Clinical Follow-up. Am J Sports Med. 2015 Jul. 43 (7):1775-83. [QxMD MEDLINE Link].
Lee SY, Kim W, Lim C, Chung SG. Treatment of Lateral Epicondylosis by Using Allogeneic Adipose-Derived Mesenchymal Stem Cells: A Pilot Study. Stem Cells. 2015 Oct. 33 (10):2995-3005. [QxMD MEDLINE Link].
Barnes DE, Beckley JM, Smith J. Percutaneous ultrasonic tenotomy for chronic elbow tendinosis: a prospective study. J Shoulder Elbow Surg. 2015 Jan. 24 (1):67-73. [QxMD MEDLINE Link].
Chesterton LS, Lewis AM, Sim J, Mallen CD, Mason EE, Hay EM, et al. Transcutaneous electrical nerve stimulation as adjunct to primary care management for tennis elbow: pragmatic randomised controlled trial (TATE trial). Br J Sports Med. 2014 Oct. 48 (19):1458. [QxMD MEDLINE Link].
Smidt N, Assendelft WJ, Arola H, et al. Effectiveness of physiotherapy for lateral epicondylitis: a systematic review. Ann Med. 2003. 35(1):51-62. [QxMD MEDLINE Link].
Dundar U, Turkmen U, Toktas H, Ulasli AM, Solak O. Effectiveness of high-intensity laser therapy and splinting in lateral epicondylitis; a prospective, randomized, controlled study. Lasers Med Sci. 2015 Apr. 30 (3):1097-107. [QxMD MEDLINE Link].
Salli A, Akkurt E, Izki AA, Şen Z, Yilmaz H. Comparison of High Intensity Laser and Epicondylitis Bandage in the Treatment of Lateral Epicondylitis. Arch Rheumatol. 2016 Sep. 31 (3):234-238. [QxMD MEDLINE Link].
Akkurt E, Kucuksen S, Yılmaz H, Parlak S, Sallı A, Karaca G. Long term effects of high intensity laser therapy in lateral epicondylitis patients. Lasers Med Sci. 2016 Feb. 31 (2):249-53. [QxMD MEDLINE Link].
Brosseau L, Casimiro L, Milne S, et al. Deep transverse friction massage for treating tendinitis. Cochrane Database Syst Rev. 2002. CD003528. [QxMD MEDLINE Link].
Sevier TL, Stegink-Jansen CW. Astym treatment vs. eccentric exercise for lateral elbow tendinopathy: a randomized controlled clinical trial. PeerJ. 2015. 3:e967. [QxMD MEDLINE Link].
Baker CL Jr, Baker CL 3rd. Long-term follow-up of arthroscopic treatment of lateral epicondylitis. Am J Sports Med. 2008 Feb. 36(2):254-60. [QxMD MEDLINE Link].
Bryant James Walrod, MD Associate Professor (Clinical), Department of Family and Community Medicine, Ohio State University College of Medicine; Team Physician, OSU Athletic Department Bryant James Walrod, MD is a member of the following medical societies: American Academy of Family Physicians, American Medical Society for Sports Medicine Disclosure: Nothing to disclose.
Rebecca Luft, BASc Ohio State University Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference Disclosure: Received salary from Medscape for employment. for: Medscape.
Craig C Young, MD Professor, Departments of Orthopedic Surgery and Community and Family Medicine, Medical Director of Sports Medicine, Medical College of Wisconsin Craig C Young, MD is a member of the following medical societies: American Academy of Family Physicians, American College of Sports Medicine, American Medical Society for Sports Medicine, Phi Beta Kappa Disclosure: Nothing to disclose.
Elbow Support Badminton Andrew D Perron, MD Residency Director, Department of Emergency Medicine, Maine Medical Center Andrew D Perron, MD is a member of the following medical societies: American College of Emergency Physicians, American College of Sports Medicine, Society for Academic Emergency Medicine Disclosure: Nothing to disclose.